Frontida site receives US FDA all-clear for former Sun Pharma site


The US Food and Drug Administration (FDA) has given the go ahead to Frontida BioPharm’s Pennsylvania, US-based site, eight months after distributing a Warning Letter for the facility.

The Warning Letter responded to evaluations made in June and July 2015, when the site was owned by Indian drug maker Sun Pharma.

Contract development and manufacturing organization Frontida acquired the Pennsylvanian site and an Illinois-based site from Sun Pharma in June, 2016, and received the FDA Warning Letter two months later.

FDA issued the Warning Letter in response to breached GMP regulations, including the release of 27 lots of clonidine HCI tablets containing potentially contaminated active pharmaceutical ingredients (APIs).

Remediation activities

Frontida COO Ron Connolly told In-PharmaTechnologist Sun Pharma had helped Frontida address the problems identified by the FDA.

“Immediately upon the acquisition, Frontida established a new quality leadership team for the operations, reorganized and added scientists to the existing laboratory teams to improve workflows, and implemented corrective and preventative actions that included investing in a new electronic quality management system,” he told us.

New products

Frontida also announced that it plans to hire an additional 40-50 personnel in the next 6 months to support planned new prescription and OTC drugs for the US and international markets.

“Frontida is also partnering with pharmaceutical companies to launch 20 products that were previously approved at the facilities. Frontida’s partners will launch seven products in the US by the end of 2017,” said Connolly.

Frontida supplies prescription and OTC products, Highly Potent Active Ingredients (HPAI), fixed-dose combination products and DEA schedules II-V products.

Related News


Teva confirms US FDA warning letter for Hangzhou, China API plant

Image: iStock/CountDuckula

Quality issues at ex-Sun Pharma plant land Frontida with US FDA warning


Sun sells two more US manufacturing plants

Sandoz will close one of the Indian plants

FDA warning letter for two Sandoz plants in India

Related Products

See more related products